Overview

To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to give patients with medullary thyroid cancer either 300mg/day or 150mg/day vandetanib and compare how well each dose affects how their cancer responds. It will also help the investigators understand the side effects of different doses in these patients.
Phase:
Phase 4
Details
Lead Sponsor:
Genzyme, a Sanofi Company